MCID: RRH023
MIFTS: 41

Rare Hereditary Hemochromatosis

Categories: Cardiovascular diseases, Endocrine diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Rare Hereditary Hemochromatosis

MalaCards integrated aliases for Rare Hereditary Hemochromatosis:

Name: Rare Hereditary Hemochromatosis 58
Iron Overload 54 6 39
Iron Overload Disease 58

Characteristics:

Orphanet epidemiological data:

58
rare hereditary hemochromatosis
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare hepatic diseases
Inborn errors of metabolism


External Ids:

ICD10 via Orphanet 33 E83.1
UMLS via Orphanet 72 C0018995 C0282193
Orphanet 58 ORPHA220489

Summaries for Rare Hereditary Hemochromatosis

MalaCards based summary : Rare Hereditary Hemochromatosis, also known as iron overload, is related to iron overload in africa and hypochromic microcytic anemia with iron overload. The drugs Hyaluronic acid and Sofosbuvir have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and heart, and related phenotypes are joint stiffness and fatigue

Related Diseases for Rare Hereditary Hemochromatosis

Diseases in the Rare Hereditary Hemochromatosis family:

Hemochromatosis, Type 1 Hemochromatosis, Type 2a
Hemochromatosis, Type 3 Hemochromatosis, Type 4
Hemochromatosis, Type 2b Hemochromatosis, Type 5
Hemochromatosis Type 2 Juvenile Hereditary Hemochromatosis
Tfr2-Related Hereditary Hemochromatosis

Diseases related to Rare Hereditary Hemochromatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 436, show less)
# Related Disease Score Top Affiliating Genes
1 iron overload in africa 13.1
2 hypochromic microcytic anemia with iron overload 13.0
3 anemia, hypochromic microcytic, with iron overload 1 12.8
4 anemia, hypochromic microcytic, with iron overload 2 12.8
5 genetic hyperferritinemia without iron overload 12.5
6 hemochromatosis, type 5 12.5
7 obsolete: rare hereditary iron overload disease 12.5
8 obsolete: hereditary iron overload with anemia 12.4
9 obsolete: hereditary iron overload with neurologic manifestation 12.4
10 hemochromatosis, type 4 11.9
11 atransferrinemia 11.9
12 hemochromatosis, type 3 11.9
13 congenital dyserythropoietic anemia 11.9
14 anemia, sideroblastic, 1 11.9
15 porphyria cutanea tarda 11.8
16 hyperferritinemia with or without cataract 11.8
17 anemia, sideroblastic, 3, pyridoxine-refractory 11.8
18 ferro-cerebro-cutaneous syndrome 11.7
19 hemochromatosis, type 2a 11.7
20 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 11.7
21 hypochromic microcytic anemia 11.6
22 variegate porphyria 11.6
23 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 11.6
24 anemia, sideroblastic, and spinocerebellar ataxia 11.6
25 anemia, sideroblastic, 2, pyridoxine-refractory 11.6
26 anemia, congenital dyserythropoietic, type ia 11.6
27 overhydrated hereditary stomatocytosis 11.5
28 anemia, congenital dyserythropoietic, type ii 11.5
29 hemochromatosis type 2 11.4
30 zellweger syndrome 11.4
31 anemia, sideroblastic, 4 11.3
32 pyridoxine-responsive sideroblastic anemia 11.3
33 myelodysplastic syndrome 10.9
34 siderosis 10.8
35 liver disease 10.8
36 deficiency anemia 10.7
37 hemosiderosis 10.7
38 atrial standstill 1 10.6
39 porphyria 10.6
40 sickle cell anemia 10.6
41 fatty liver disease 10.6
42 aplastic anemia 10.5
43 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.5
44 sideroblastic anemia 10.5
45 hepatocellular carcinoma 10.5
46 viral hepatitis 10.5
47 hemolytic anemia 10.5
48 arthropathy 10.5
49 non-alcoholic fatty liver disease 10.5
50 graft-versus-host disease 10.5
51 hypothyroidism 10.5
52 hepatitis c virus 10.4
53 fatty liver disease, nonalcoholic 1 10.4
54 hemochromatosis, type 1 10.4
55 granulocytopenia 10.4
56 refractory anemia 10.4
57 leukemia, acute myeloid 10.4
58 iron deficiency anemia 10.4
59 exanthem 10.4
60 non-alcoholic steatohepatitis 10.4
61 neutropenia 10.4
62 end stage renal failure 10.4
63 microcytic anemia 10.4
64 congestive heart failure 10.4
65 splenomegaly 10.4
66 acute leukemia 10.4
67 tfr2-related hereditary hemochromatosis 10.4
68 thalassemia 10.3
69 pyruvate kinase deficiency of red cells 10.3
70 bone disease 10.3
71 osteoporosis 10.3
72 myelofibrosis 10.3
73 bone mineral density quantitative trait locus 8 10.3
74 bone mineral density quantitative trait locus 15 10.3
75 bone resorption disease 10.3
76 hypoparathyroidism 10.3
77 cataract 10.3
78 mucormycosis 10.3
79 myeloid leukemia 10.3
80 atherosclerosis susceptibility 10.2
81 fibrosis of extraocular muscles, congenital, 1 10.2
82 proteasome-associated autoinflammatory syndrome 1 10.2
83 microvascular complications of diabetes 7 10.2
84 pulmonary hypertension 10.2
85 hepatic veno-occlusive disease 10.2
86 lymphocytic leukemia 10.2
87 bacterial infectious disease 10.2
88 hereditary spherocytosis 10.2
89 pure red-cell aplasia 10.2
90 cholestasis 10.2
91 amenorrhea 10.2
92 impotence 10.2
93 endometriosis 10.2
94 juvenile hereditary hemochromatosis 10.2
95 chronic graft versus host disease 10.2
96 red cell aplasia 10.2
97 beta-thalassemia 10.2
98 hypercholesterolemia, familial, 1 10.2
99 hypogonadotropic hypogonadism 10.2
100 hyperinsulinism 10.2
101 hemoglobin e disease 10.2
102 kidney disease 10.2
103 alzheimer disease 10.2
104 friedreich ataxia 10.2
105 macular degeneration, age-related, 1 10.2
106 alpha-thalassemia 10.2
107 leukemia, acute lymphoblastic 10.2
108 heart disease 10.2
109 listeriosis 10.2
110 diarrhea 10.2
111 hepatitis 10.2
112 myopathy 10.2
113 pituitary gland disease 10.2
114 retinal degeneration 10.2
115 acute graft versus host disease 10.2
116 aregenerative anemia 10.2
117 alcohol dependence 10.1
118 hemoglobin h disease 10.1
119 transferrin serum level quantitative trait locus 2 10.1
120 mucositis 10.1
121 portal hypertension 10.1
122 dilated cardiomyopathy 10.1
123 autoimmune hepatitis 10.1
124 hyperglycemia 10.1
125 adenoma 10.1
126 47,xyy 10.1
127 vibrio vulnificus infection 10.1
128 brain injury 10.1
129 iron metabolism disease 10.1
130 hypertriglyceridemia, familial 10.1
131 dowling-degos disease 1 10.1
132 arterial calcification, generalized, of infancy, 1 10.1
133 fanconi anemia, complementation group a 10.1
134 hypoascorbemia 10.1
135 microvascular complications of diabetes 5 10.1
136 hydrops, lactic acidosis, and sideroblastic anemia 10.1
137 osteomalacia 10.1
138 alcoholic hepatitis 10.1
139 leukemia 10.1
140 pancytopenia 10.1
141 hyperparathyroidism 10.1
142 toxic shock syndrome 10.1
143 hepatitis b 10.1
144 benign mesothelioma 10.1
145 bilirubin metabolic disorder 10.1
146 adenocarcinoma 10.1
147 lipid metabolism disorder 10.1
148 uremia 10.1
149 brain edema 10.1
150 retinal disease 10.1
151 hypersplenism 10.1
152 neuroblastoma 10.1
153 peritonitis 10.1
154 diabetes mellitus 10.1
155 48,xyyy 10.1
156 congenital hemolytic anemia 10.1
157 cryptogenic cirrhosis 10.1
158 spinal cord injury 10.1
159 ataxia and polyneuropathy, adult-onset 10.0
160 gracile syndrome 10.0
161 aceruloplasminemia 10.0
162 lactic acidosis 10.0
163 aminoaciduria 10.0
164 spondyloarthropathy 1 10.0
165 autoimmune disease 10.0
166 diabetes mellitus, noninsulin-dependent 10.0
167 multiple sclerosis 10.0
168 mesothelioma, malignant 10.0
169 ovarian cancer 10.0
170 porphyria cutanea tarda, type i 10.0
171 spherocytosis, type 1 10.0
172 triiodothyronine receptor auxiliary protein 10.0
173 anemia, autoimmune hemolytic 10.0
174 neurodegeneration with brain iron accumulation 1 10.0
175 hydrops fetalis, nonimmune 10.0
176 wilson disease 10.0
177 yemenite deaf-blind hypopigmentation syndrome 10.0
178 abdominal obesity-metabolic syndrome 1 10.0
179 neurodegeneration with brain iron accumulation 3 10.0
180 body mass index quantitative trait locus 1 10.0
181 coronary heart disease 1 10.0
182 microvascular complications of diabetes 3 10.0
183 microvascular complications of diabetes 4 10.0
184 microvascular complications of diabetes 6 10.0
185 alpha-1-antitrypsin deficiency 10.0
186 aspergillosis 10.0
187 lung disease, immunodeficiency, and chromosome breakage syndrome 10.0
188 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
189 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
190 invasive aspergillosis 10.0
191 atrioventricular block 10.0
192 hepatocellular adenoma 10.0
193 cardiac arrest 10.0
194 meningoencephalitis 10.0
195 glucose intolerance 10.0
196 chondrocalcinosis 10.0
197 cryptococcosis 10.0
198 inflammatory spondylopathy 10.0
199 primary biliary cirrhosis 10.0
200 cutaneous porphyria 10.0
201 squamous cell papilloma 10.0
202 candidiasis 10.0
203 papilloma 10.0
204 glucosephosphate dehydrogenase deficiency 10.0
205 glomerulonephritis 10.0
206 osteitis fibrosa 10.0
207 bone inflammation disease 10.0
208 plague 10.0
209 calciphylaxis 10.0
210 peripheral nervous system disease 10.0
211 spondylitis 10.0
212 cerebrovascular disease 10.0
213 chronic kidney disease 10.0
214 neuropathy 10.0
215 hypoglycemia 10.0
216 allergic encephalomyelitis 10.0
217 growth hormone deficiency 10.0
218 tremor 10.0
219 rapidly involuting congenital hemangioma 10.0
220 argyria 10.0
221 hemochromatosis, neonatal 9.9
222 autosomal recessive disease 9.9
223 diamond-blackfan anemia 9.9
224 alcohol use disorder 9.9
225 hepatitis c 9.9
226 hypogonadism 9.9
227 hemoglobinopathy 9.9
228 movement disease 9.9
229 liver cirrhosis 9.9
230 hypogonadotropism 9.9
231 viral infectious disease 9.9
232 sickle cell disease 9.9
233 cytomegalovirus infection 9.9
234 aortic aneurysm, familial abdominal, 1 9.8
235 amyotrophic lateral sclerosis 1 9.8
236 arteries, anomalies of 9.8
237 colorectal cancer 9.8
238 cardiac arrhythmia 9.8
239 cardiac conduction defect 9.8
240 major affective disorder 1 9.8
241 hirschsprung disease 1 9.8
242 huntington disease 9.8
243 endosteal hyperostosis, autosomal dominant 9.8
244 hypertension, essential 9.8
245 chromosome 5q deletion syndrome 9.8
246 optic atrophy 1 9.8
247 platelet membrane fluidity 9.8
248 protoporphyria, erythropoietic, 1 9.8
249 pulmonary hemosiderosis 9.8
250 sarcoidosis 1 9.8
251 thrombophilia due to activated protein c resistance 9.8
252 down syndrome 9.8
253 tuberous sclerosis 1 9.8
254 iron-refractory iron deficiency anemia 9.8
255 celiac disease 1 9.8
256 chondrodysplasia punctata syndrome 9.8
257 enterocolitis 9.8
258 gaucher disease, type i 9.8
259 dubin-johnson syndrome 9.8
260 hyperbilirubinemia, shunt, primary 9.8
261 cartilage-hair hypoplasia 9.8
262 mitochondrial dna depletion syndrome 3 9.8
263 myeloma, multiple 9.8
264 porphyria, congenital erythropoietic 9.8
265 renal tubular dysgenesis 9.8
266 tyrosinemia, type i 9.8
267 protoporphyria, erythropoietic, x-linked 9.8
268 multiple congenital anomalies-hypotonia-seizures syndrome 2 9.8
269 aging 9.8
270 stroke, ischemic 9.8
271 acute insulin response 9.8
272 branchiootic syndrome 1 9.8
273 dyskinesia, familial, with facial myokymia 9.8
274 pulmonary disease, chronic obstructive 9.8
275 kala-azar 1 9.8
276 malaria 9.8
277 diabetes mellitus, ketosis-prone 9.8
278 pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis 9.8
279 cholangitis, primary sclerosing 9.8
280 heme oxygenase 1 deficiency 9.8
281 membranous nephropathy 9.8
282 hyperproinsulinemia 9.8
283 chorea, childhood-onset, with psychomotor retardation 9.8
284 retinitis pigmentosa and erythrocytic microcytosis 9.8
285 hyperlipoproteinemia, type iii 9.8
286 helix syndrome 9.8
287 erythrocytosis, familial, 6 9.8
288 angiosarcoma 9.8
289 hemophagocytic lymphohistiocytosis 9.8
290 restless legs syndrome 9.8
291 adult t-cell leukemia 9.8
292 inflammatory bowel disease 9.8
293 rheumatic heart disease 9.8
294 lymphoma 9.8
295 generalized epilepsy with febrile seizures plus 9.8
296 atrial fibrillation 9.8
297 ptosis 9.8
298 x-linked chondrodysplasia punctata 1 9.8
299 chronic myelomonocytic leukemia 9.8
300 neurodegeneration with brain iron accumulation 9.8
301 asbestosis 9.8
302 pre-eclampsia 9.8
303 interstitial nephritis 9.8
304 hydrocephalus 9.8
305 placenta praevia 9.8
306 cholecystolithiasis 9.8
307 vitamin k deficiency bleeding 9.8
308 adult respiratory distress syndrome 9.8
309 endometriosis of ovary 9.8
310 hemopericardium 9.8
311 cardiac tamponade 9.8
312 infant gynecomastia 9.8
313 choledocholithiasis 9.8
314 pericardial effusion 9.8
315 coronary artery anomaly 9.8
316 esophagitis 9.8
317 chagas disease 9.8
318 common variable immunodeficiency 9.8
319 spinal muscular atrophy 9.8
320 secondary hyperparathyroidism 9.8
321 gynecomastia 9.8
322 choreatic disease 9.8
323 acute cystitis 9.8
324 typhoid fever 9.8
325 tuberous sclerosis 9.8
326 obstructive jaundice 9.8
327 biliary atresia 9.8
328 clonorchiasis 9.8
329 polyneuropathy 9.8
330 sclerosing cholangitis 9.8
331 acute chest syndrome 9.8
332 thrombocytopenia 9.8
333 duodenal ulcer 9.8
334 mitral valve stenosis 9.8
335 epilepsy 9.8
336 gaucher's disease 9.8
337 hypothalamic disease 9.8
338 cholecystitis 9.8
339 hepatitis d 9.8
340 intestinal perforation 9.8
341 myeloproliferative neoplasm 9.8
342 lateral sclerosis 9.8
343 colon adenocarcinoma 9.8
344 macrocytic anemia 9.8
345 thrombophilia 9.8
346 motor peripheral neuropathy 9.8
347 sensory peripheral neuropathy 9.8
348 hematologic cancer 9.8
349 hemangioma 9.8
350 kidney cancer 9.8
351 bronchiolitis obliterans 9.8
352 long qt syndrome 9.8
353 bronchiolitis 9.8
354 acute kidney failure 9.8
355 interstitial lung disease 9.8
356 demyelinating disease 9.8
357 ischemia 9.8
358 purpura 9.8
359 aortic aneurysm 9.8
360 restrictive cardiomyopathy 9.8
361 syphilis 9.8
362 rh isoimmunization 9.8
363 pancreatitis 9.8
364 infertility 9.8
365 human immunodeficiency virus infectious disease 9.8
366 pneumonia 9.8
367 t-cell adult acute lymphocytic leukemia 9.8
368 adenosine deaminase deficiency 9.8
369 severe combined immunodeficiency 9.8
370 acquired immunodeficiency syndrome 9.8
371 mitochondrial metabolism disease 9.8
372 t-cell leukemia 9.8
373 monoclonal gammopathy of uncertain significance 9.8
374 muscular atrophy 9.8
375 childhood leukemia 9.8
376 placenta disease 9.8
377 hyperthyroidism 9.8
378 septic arthritis 9.8
379 myocarditis 9.8
380 appendicitis 9.8
381 osteoarthritis 9.8
382 lung disease 9.8
383 rubella 9.8
384 fascioliasis 9.8
385 evans' syndrome 9.8
386 hepatopulmonary syndrome 9.8
387 leishmaniasis 9.8
388 cutaneous leishmaniasis 9.8
389 peliosis hepatis 9.8
390 visceral leishmaniasis 9.8
391 tyrosinemia 9.8
392 priapism 9.8
393 hypopituitarism 9.8
394 cholangitis 9.8
395 meningitis 9.8
396 pulmonary embolism 9.8
397 encephalitis 9.8
398 fasciitis 9.8
399 necrotizing fasciitis 9.8
400 yellow fever 9.8
401 biliary tract disease 9.8
402 irritable bowel syndrome 9.8
403 toxoplasmosis 9.8
404 hemophilia 9.8
405 adcy5-related dyskinesia 9.8
406 cartilage-hair hypoplasia - anauxetic dysplasia spectrum disorders 9.8
407 erythropoietic protoporphyria, autosomal recessive 9.8
408 familial porphyria cutanea tarda 9.8
409 hypertrophic cardiomyopathy 9.8
410 mitochondrial disorders 9.8
411 slc39a14 deficiency 9.8
412 x-linked protoporphyria 9.8
413 chronic thromboembolic pulmonary hypertension 9.8
414 cytokine deficiency 9.8
415 inherited bone marrow failure syndromes 9.8
416 myelodysplastic syndrome with excess blasts 9.8
417 warfarin syndrome 9.8
418 depression 9.8
419 aneurysm 9.8
420 anoxia 9.8
421 chronic pain 9.8
422 encephalopathy 9.8
423 hypotonia 9.8
424 hypoxia 9.8
425 spasticity 9.8
426 traumatic brain injury 9.8
427 asbestos intoxication 9.8
428 secondary hemophagocytic lymphohistiocytosis 9.8
429 autosomal recessive sideroblastic anemia 9.8
430 pik3ca-related overgrowth syndrome 9.8
431 acute liver failure 9.8
432 renal dysplasia 9.8
433 premature aging 9.8
434 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.8
435 refractory cytopenia with multilineage dysplasia 9.8
436 chronic hepatic porphyria 9.8

Graphical network of the top 20 diseases related to Rare Hereditary Hemochromatosis:



Diseases related to Rare Hereditary Hemochromatosis

Symptoms & Phenotypes for Rare Hereditary Hemochromatosis

Human phenotypes related to Rare Hereditary Hemochromatosis:

58 31 (showing 13, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001387
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 joint swelling 58 31 hallmark (90%) Very frequent (99-80%) HP:0001386
4 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
5 hypogonadotrophic hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000044
6 generalized hyperpigmentation 58 31 hallmark (90%) Very frequent (99-80%) HP:0007440
7 increased serum ferritin 58 31 hallmark (90%) Very frequent (99-80%) HP:0003281
8 osteoporosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000939
9 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
10 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
11 congenital hepatic fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002612
12 neoplasm of the liver 58 31 occasional (7.5%) Occasional (29-5%) HP:0002896
13 abnormal joint morphology 58 Very frequent (99-80%)

Drugs & Therapeutics for Rare Hereditary Hemochromatosis

Drugs for Rare Hereditary Hemochromatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 173, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
2
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
3
Ledipasvir Approved Phase 4 1256388-51-8 67505836
4
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
5
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
6
Metformin Approved Phase 4 657-24-9 4091 14219
7
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
8
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
11
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
12 Anticoagulants Phase 4
13 Dextrans Phase 4
14 Plasma Substitutes Phase 4
15 Blood Substitutes Phase 4
16 Iron-Dextran Complex Phase 4
17 Antiviral Agents Phase 4
18 Sofosbuvir-velpatasvir drug combination Phase 4
19 Lactoferrin Phase 4
20 Ledipasvir, sofosbuvir drug combination Phase 4
21 Liver Extracts Phase 4
22 Siderophores Phase 4
23 Hypoglycemic Agents Phase 4
24 Antilymphocyte Serum Phase 4
25 Pharmaceutical Solutions Phase 4
26 Vitamins Phase 4
27 Antioxidants Phase 4
28 Iron Supplement Phase 4
29 Nutrients Phase 4
30 Trace Elements Phase 4
31 Micronutrients Phase 4
32 Chelating Agents Phase 4
33 Iron Chelating Agents Phase 4
34 Anti-Infective Agents Phase 4
35 Immunologic Factors Phase 4
36 Antifungal Agents Phase 4
37 Dermatologic Agents Phase 4
38 Antirheumatic Agents Phase 4
39 Immunosuppressive Agents Phase 4
40 Cyclosporins Phase 4
41 Calcineurin Inhibitors Phase 4
42 Central Nervous System Stimulants Phase 4
43
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
44
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
45 Orange Approved Phase 3
46
Amlodipine Approved Phase 3 88150-42-9 2162
47
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
48
Hydroxyurea Approved Phase 3 127-07-1 3657
49
tannic acid Approved Phase 3 1401-55-4
50
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
51 Hematinics Phase 2, Phase 3
52 Adjuvants, Immunologic Phase 2, Phase 3
53 Zinc Supplement Phase 3
54 Vasodilator Agents Phase 3
55 calcium channel blockers Phase 3
56 Antihypertensive Agents Phase 3
57 Epoetin alfa Phase 2, Phase 3 113427-24-0
58 Immunoglobulin Fc Fragments Phase 3
59
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
60
Ethanol Approved Phase 2 64-17-5 702
61
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
62
Mycophenolic acid Approved Phase 2 24280-93-1 446541
63
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
64
Copper Approved, Investigational Phase 2 7440-50-8 27099
65
Disulfiram Approved Phase 2 97-77-8 3117
66
Deferiprone Approved Phase 2 30652-11-0 2972
67
Ferrous succinate Approved Phase 2 10030-90-7
68
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
69
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
70
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
71
alemtuzumab Approved, Investigational Phase 2 216503-57-0
72
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
73
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
74
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
75
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
76
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
77
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
78
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 59-43-8, 70-16-6 1130
79
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
80
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
81 Vitamin B 6 Phase 2
82 Diphosphonates Phase 2
83 Fibrinolytic Agents Phase 2
84 Tissue Plasminogen Activator Phase 2
85 Plasminogen Phase 2
86 Liposomal amphotericin B Phase 2
87 Antiparasitic Agents Phase 2
88 Antiprotozoal Agents Phase 2
89 Ferrosoferric Oxide Phase 2
90 Parenteral Nutrition Solutions Phase 2
91 Calcium, Dietary Phase 2
92 Protective Agents Phase 2
93 Ergocalciferols Phase 2
94 Vitamin D2 Phase 2
95 Calciferol Phase 2
96 Thymoglobulin Phase 2
97 Vitamin B Complex Phase 2
98 Vitamin B9 Phase 2
99 Folate Phase 2
100 Thiamin Phase 2
101 Hepcidins Phase 2
102 Trichostatin A Phase 2
103 Antimetabolites Phase 2
104 Alkylating Agents Phase 2
105 Interleukin 1 Receptor Antagonist Protein Phase 2
106 Anti-Bacterial Agents Phase 2
107 Antineoplastic Agents, Immunological Phase 2
108 Ferric Compounds Phase 2
109 Antibiotics, Antitubercular Phase 2
110
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
111
Nifedipine Approved Phase 1 21829-25-4 4485
112
Zinc sulfate Approved, Investigational Phase 1 7733-02-0
113
Azathioprine Approved Phase 1 446-86-6 2265
114 Tocolytic Agents Phase 1
115 silymarin Phase 1
116 Muromonab-CD3 Phase 1
117 pyruvate Phase 1
118
Pantoprazole Approved 102625-70-7 4679
119
Polyestradiol phosphate Approved 28014-46-2
120
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
121
Testosterone Approved, Experimental, Investigational 58-22-0, 481-30-1 6013 10204
122 Papaya Approved
123
Aspirin Approved, Vet_approved 50-78-2 2244
124
Zinc Approved, Investigational 7440-66-6 32051
125
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
126
Calcium carbonate Approved, Investigational 471-34-1
127
Simeprevir Approved 923604-59-5 66576988
128
Ribavirin Approved 36791-04-5 37542
129
Sodium citrate Approved, Investigational 68-04-2
130
Acetylcysteine Approved, Investigational 616-91-1 12035
131
Regadenoson Approved, Investigational 313348-27-5 219024
132
Acetazolamide Approved, Vet_approved 59-66-5 1986
133
Fludarabine Approved 21679-14-1, 75607-67-9 30751
134
Busulfan Approved, Investigational 55-98-1 2478
135
Mesna Approved, Investigational 3375-50-6 598
136
rituximab Approved 174722-31-7 10201696
137
Bortezomib Approved, Investigational 179324-69-7 93860 387447
138
Cytarabine Approved, Experimental, Investigational 147-94-4, 65-46-3 6253
139
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985